Cargando…

Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report

BACKGROUND: The optimal treatment of serpiginous choroiditis is not established. While recent reports indicate the efficacy of adalimumab, there is limited evidence. We present a case of serpiginous choroiditis refractory to steroids, immunosuppressants, and adalimumab. CASE PRESENTATION: An 18-year...

Descripción completa

Detalles Bibliográficos
Autores principales: Noda, Kazunori, Oishi, Akio, Uji, Akihito, Tanaka, Saori, Tsujikawa, Akitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480770/
https://www.ncbi.nlm.nih.gov/pubmed/31014297
http://dx.doi.org/10.1186/s12886-019-1104-3
_version_ 1783413641941352448
author Noda, Kazunori
Oishi, Akio
Uji, Akihito
Tanaka, Saori
Tsujikawa, Akitaka
author_facet Noda, Kazunori
Oishi, Akio
Uji, Akihito
Tanaka, Saori
Tsujikawa, Akitaka
author_sort Noda, Kazunori
collection PubMed
description BACKGROUND: The optimal treatment of serpiginous choroiditis is not established. While recent reports indicate the efficacy of adalimumab, there is limited evidence. We present a case of serpiginous choroiditis refractory to steroids, immunosuppressants, and adalimumab. CASE PRESENTATION: An 18-year-old woman presented with severe vision loss in both eyes. A fundus examination revealed a foveal grayish-white lesion, and optical coherence tomography revealed outer retinal damage. She was diagnosed with serpiginous choroiditis and treated with steroid pulse therapy, but the disease progressed continuously. The addition of sub-Tenon’s injection of triamcinolone and oral cyclosporine did not change the disease course. We also administered subcutaneous injections of adalimumab, but even with the intensive treatment, the retinal lesions and subsequent atrophy progressed. Her right and left visual acuity declined from 20/22 to 20/66 and 20/200, respectively, during the 9 months of follow-up. CONCLUSION: Here, we report a case of serpiginous choroiditis refractory to corticosteroids, immunosuppressants, and adalimumab. Further studies are needed to establish the optimal treatment for such cases.
format Online
Article
Text
id pubmed-6480770
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64807702019-05-01 Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report Noda, Kazunori Oishi, Akio Uji, Akihito Tanaka, Saori Tsujikawa, Akitaka BMC Ophthalmol Case Report BACKGROUND: The optimal treatment of serpiginous choroiditis is not established. While recent reports indicate the efficacy of adalimumab, there is limited evidence. We present a case of serpiginous choroiditis refractory to steroids, immunosuppressants, and adalimumab. CASE PRESENTATION: An 18-year-old woman presented with severe vision loss in both eyes. A fundus examination revealed a foveal grayish-white lesion, and optical coherence tomography revealed outer retinal damage. She was diagnosed with serpiginous choroiditis and treated with steroid pulse therapy, but the disease progressed continuously. The addition of sub-Tenon’s injection of triamcinolone and oral cyclosporine did not change the disease course. We also administered subcutaneous injections of adalimumab, but even with the intensive treatment, the retinal lesions and subsequent atrophy progressed. Her right and left visual acuity declined from 20/22 to 20/66 and 20/200, respectively, during the 9 months of follow-up. CONCLUSION: Here, we report a case of serpiginous choroiditis refractory to corticosteroids, immunosuppressants, and adalimumab. Further studies are needed to establish the optimal treatment for such cases. BioMed Central 2019-04-24 /pmc/articles/PMC6480770/ /pubmed/31014297 http://dx.doi.org/10.1186/s12886-019-1104-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Noda, Kazunori
Oishi, Akio
Uji, Akihito
Tanaka, Saori
Tsujikawa, Akitaka
Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title_full Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title_fullStr Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title_full_unstemmed Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title_short Limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
title_sort limited efficacy of adalimumab in the acute phase of serpiginous choroiditis refractory to corticosteroid and cyclosporine, a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480770/
https://www.ncbi.nlm.nih.gov/pubmed/31014297
http://dx.doi.org/10.1186/s12886-019-1104-3
work_keys_str_mv AT nodakazunori limitedefficacyofadalimumabintheacutephaseofserpiginouschoroiditisrefractorytocorticosteroidandcyclosporineacasereport
AT oishiakio limitedefficacyofadalimumabintheacutephaseofserpiginouschoroiditisrefractorytocorticosteroidandcyclosporineacasereport
AT ujiakihito limitedefficacyofadalimumabintheacutephaseofserpiginouschoroiditisrefractorytocorticosteroidandcyclosporineacasereport
AT tanakasaori limitedefficacyofadalimumabintheacutephaseofserpiginouschoroiditisrefractorytocorticosteroidandcyclosporineacasereport
AT tsujikawaakitaka limitedefficacyofadalimumabintheacutephaseofserpiginouschoroiditisrefractorytocorticosteroidandcyclosporineacasereport